---
title: "Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash Merger"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290948205.md"
description: "Bio-Techne has entered into an agreement to be acquired by Merck, Darmstadt, Germany, in an all-cash merger valued at $73.00 per share. Upon completion, subject to shareholder approval and regulatory clearances, Bio-Techne will become a wholly owned subsidiary of Merck. The deal aims to provide immediate cash value and strategic scale."
datetime: "2026-06-26T10:03:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290948205.md)
  - [en](https://longbridge.com/en/news/290948205.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290948205.md)
---

# Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash Merger

Bio-Techne entered into an Agreement and Plan of Merger with Merck, Darmstadt, Germany, under which Merck will acquire Bio-Techne for $73.00 per share in cash. Following the merger, Bio-Techne will become a wholly owned subsidiary of Merck, subject to shareholder approval and customary regulatory clearances. The agreement includes customary terms, closing conditions, and termination fee provisions for both parties.

**Agreement details:**

-   **Agreement type**: Agreement and Plan of Merger (all-cash acquisition)
-   **Counterparty**: Merck, Darmstadt, Germany
-   **Signed / Effective**: Jun 25 2026 / N/A
-   **Reason**: Provide immediate cash value and strategic scale under Merck

Original SEC Filing: BIO-TECHNE Corp \[ TECH \] - 8-K - Jun. 25, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [MRK.DE](https://longbridge.com/en/quote/MRK.DE.md)

## Related News & Research

- [Barclays Reaffirms Their Hold Rating on Merck KGaA (0O14)](https://longbridge.com/en/news/290923195.md)
- [Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel](https://longbridge.com/en/news/290948213.md)
- [Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion](https://longbridge.com/en/news/290850358.md)
- [Merck KGaA partners with Versant-backed Saturnus Bio in $50 million genetic cardiomyopathy deal](https://longbridge.com/en/news/290572135.md)
- [15:11 ETAbu Dhabi Announces Partnership with MSD to Advance Operational Excellence and Expand Access across the Region](https://longbridge.com/en/news/290730659.md)